Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.

Breast cancer research : BCR·2026

Same author

Worsening frailty and declining quality of life in older survivors of non-metastatic breast cancer.

Journal of the National Cancer Institute·2026

Same author

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA oncology·2026

Same author

ASO Visual Abstract: From Clinical Trial Awareness to Practice-Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial.

Annals of surgical oncology·2026

Same author

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

medRxiv : the preprint server for health sciences·2026

Same author

Multidisciplinary clinics in cancer-models, metrics, and meaning: a review.

The oncologist·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

The E75 HER2/neu peptide vaccine.

Elizabeth A Mittendorf¹, Jarrod P Holmes, Sathibalan Ponniah

¹Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

Cancer Immunology, Immunotherapy : CII

|June 10, 2008

Summary

This summary is machine-generated.

The E75 peptide vaccine, combined with GM-CSF, was evaluated in breast cancer patients to prevent recurrence. The study reviewed safety, immune response, and clinical benefits, offering insights for future cancer vaccine development.

More Related Videos

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jul 4, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Area of Science:

Oncology
Immunology
Vaccine Development

Background:

HER2/neu protein overexpression is common in breast cancer.
E75 peptide is an immunogenic component of HER2/neu.
Previous studies explored E75 peptide vaccine potential.

Purpose of the Study:

To assess the E75 vaccine's efficacy in preventing disease recurrence in high-risk breast cancer patients.
To review the safety and immunologic response to the E75 + GM-CSF vaccine.
To discuss potential clinical benefits and lessons learned from Phase II trials.

Main Methods:

Two concurrent Phase II clinical trials involving 186 disease-free breast cancer patients (node-positive and node-negative).
Evaluation of vaccine safety, immunologic response, recurrence rates, and mortality.
Analysis of optimal dosing and need for booster inoculations.

Main Results:

Discussion of recurrence rates, mortality associated with recurrence, and recurrence distribution.
Presentation of data on the potential clinical utility of the single epitope vaccine.
Exploration of mechanisms behind the vaccine's potential clinical benefit.

Conclusions:

The review synthesizes findings on the E75 + GM-CSF vaccine's safety, immunogenicity, and clinical impact.
Identified key lessons for optimizing dosing and booster strategies.
Outlines future directions, including multi-epitope vaccines and combination immunotherapies.